The limb-girdle muscular dystrophies

Neurologic Clinics

Volumn 32, Issue 3, 2014, Pages 729-749

  Wicklund, Matthew P ^a   Kissel, John T ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Anoctamin 5; Calpain 3; Dysferlin; Fukutin related protein; Lamin A C; Limb girdle muscular dystrophy; Sarcoglycan

Indexed keywords

ANOCTAMIN 5; CALPAIN; DYSFERLIN; DYSTROGLYCAN; FUKUTIN RELATED PROTEIN; LAMIN A; LAMIN C; SARCOGLYCAN; UNCLASSIFIED DRUG; MUSCLE PROTEIN;

EXTRACELLULAR MATRIX; GENE SEQUENCE; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; SARCOLEMMA; SARCOMERE; SARCOPLASM; ADOLESCENT; ADULT; CASE REPORT; CHILD; FEMALE; GENETICS; MALE; MIDDLE AGED; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION; ONSET AGE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION; YOUNG ADULT;

EID: 84904330233     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.04.005     Document Type: Review

References (99)

1. Bushby K.M. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord 1995, 5:71-74.
2. Bushby K.M., Beckmann J.S. The limb-girdle muscular dystrophies - proposal for a new nomenclature. Neuromuscul Disord 1995, 5:337-343.
3. Wicklund M., DiVincenzo C., Liaquat K., et al. Relative prevalence of limb girdle muscular dystrophies in the United States population. Neurology 2013, 80. P07.030.
4. Norwood F., Harling C., Chinnery P., et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009, 132:3175-3186.
5. Krahn M., Lopez de Munain A., Streichenberger N., et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006, 59:905-911.
6. Amato A.A. Adults with eosinophilic myositis and calpain-3 mutations. Neurology 2008, 70:730-731.
7. Richard I., Broux O., Allamand V., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995, 81:27-40.
8. Beckmann J., Spencer M. Calpain 3, the "gatekeeper" of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 2008, 18:913-921.
9. Hauerslev S., Sveen M.L., Duno M., et al. Calpain 3 is important for muscle regeneration: evidence from patients with limb girdle muscular dystrophies. BMC Musculoskelet Disord 2012, 13:43.
10. Fardeau M., Hillaire D., Mignard C., et al. Juvenile limb-girdle muscular dystrophy: clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996, 119:295-308.
11. Pollitt C., Anderson L.V., Pogue R., et al. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul Disord 2001, 11:287-296.
12. Dirik E., Aydin A., Kurul S., et al. Limb girdle muscular dystrophy type 2A presenting with cardiac arrest. Pediatr Neurol 2001, 24:235-237.
13. Leidenroth A., Sorte H., Gilfillan G., et al. Diagnosis by sequencing: correction of misdiagnosis of FSHD2 to LGMD2A by whole-exome analysis. Eur J Hum Genet 2012, 20:999-1003.
14. Fanin M., Nascimbeni A., Fulizio L., et al. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord 2005, 15:218-224.
15. ten Dam L., van der Kooi A., van Wattingen M., et al. Reliability and accuracy of skeletal muscle imaging in limb-girdle muscular dystrophies. Neurology 2012, 79:1716-1723.
16. Nadaj-Pakleza A., Dorobek M., Nestorowicz K., et al. Muscle pathology in 31 patients with calpain 3 gene mutations. Neurol Neurochir Pol 2013, 47:214-222.
17. Richard I., Roudaut C., Saenz A., et al. Calpainopathy - a survey of mutations and polymorphisms. Am J Hum Genet 1999, 64:1524-1540.
18. Kramerova I., Beckmann J.S., Spencer M.J. Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochimica et Biophysica Acta 2007, 1772:128-144.
19. Oflazer P.S., Gundesli H., Zorludemir S., et al. Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the natural course of the dystrophic disease?. Neuromuscul Disord 2009, 19:261-263.
20. Liu J., Aoki M., Illa I., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998, 20:31-36.
21. Bansal D., Miyake K., Vogel S.S., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
22. Lostal W., Bartoli M., Roudaut C., et al. Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One 2012, 7:e38036.
23. Chiu Y., Hornsey M., Klinge L., et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009, 18:1976-1989.
24. De Luna N., Gallardo E., Soriano M., et al. Absence of dysferlin alters myogenin expression and delays human muscle differentiation "Invitro". JBiol Chem 2006, 281:17092-17098.
25. Klinge L., Harris J., Sewry C.A., et al. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 2010, 41:166-173.
26. Guglieri M., Magri F., Grazia D'Angelo M., et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008, 29:258-266.
27. Illa I., Serrano-Munuera C., Gallardo E., et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001, 49:130-134.
28. Nguyen K., Bassez G., Krahn M., et al. Phenotypic study in 40 patients with dysferlin gene mutations. Arch Neurol 2007, 64:1176-1182.
29. Krahn M., Béroud C., Labelle V., et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2008, 30:E345-E375.
30. Rosales X., Gastier-Foster J., Lewis S., et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010, 42:14-21.
31. Klinge L., Aboumousa A., Eagle M., et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. JNeurol Neurosurg Psychiatry 2010, 81:946-953.
32. Paradas C., González-Quereda L., De Luna N., et al. Anew phenotype of dysferlinopathy with congenital onset. Neuromuscul Disord 2009, 19:21-25.
33. Klinge L., Dean A.F., Kress W., et al. Late onset dyferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008, 18:288-290.
34. Suzuki N., Takahashi T., Suzuki Y., et al. An autopsy case of a dysferlinopathy patient with cardiac involvement. Muscle Nerve 2012, 45:298-299.
35. Takahashi T., Aoki M., Suzuki N., et al. Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. JNeurol Neurosurg Psychiatry 2013, 84:433-440.
36. Shaibani A., Harati Y., Amato A., et al. Miyoshi myopathy with vacuoles. Neurology 1997, 47(Suppl):A195.
37. Spuler S., Carl M., Zabojszcza J., et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008, 63:323-328.
38. McNally E.M., Ly C.T., Rosenmann H., et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000, 91:305-312.
39. Gallardo E., Rojas-García R., de Luna N., et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138.
40. Vinit J., Samson M., Gaultier J.B., et al. Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 2010, 29:103-106.
41. Nilsson M.E., Laureano M.L., Saeed M., et al. Dysferlin aggregation in limb-girdle muscular dystrophy type 2B/Myoshi myopathy necessitates mutational screen for diagnosis. Muscle Nerve 2013, 47:740-747.
42. Walter M.C., Reilich P., Thiele S., et al. Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 2013, 8:26.
43. Ervasti J.M., Campbell K.P. Arole for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. JCell Biol 1993, 122:809-823.
44. Crosbie R.H., Lim L.E., Moore S.A., et al. Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions. Hum Mol Genet 2000, 9:2019-2027.
45. Moore S.A., Schilling C.J., Westra S., et al. Limb-girdle muscular dystrophy in the United States. JNeuropathol Exp Neurol 2006, 65:995-1003.
46. Merlini L., Kaplan J.C., Navarro C., et al. Homogeneous phenotype of the gypsy limb-girdle MD with the g-sarcoglycan C283Y mutation. Neurology 2000, 54:1075-1079.
47. McNally E.M., Passos-Bueno M.R., Bönneman C.G., et al. Mild and severe muscular dystrophy caused by a single γ-sarcoglycan mutation. Am J Hum Genet 1996, 59:1040-1047.
48. Kefi M., Amouri R., Driss A., et al. Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation. Neuromuscul Disord 2003, 13:779-787.
49. Mongini T., Doriguzzi C., Bosone I., et al. Alpha-sarcoglycan deficiency featuring exercise intolerance and myoglobinuria. Neuropediatrics 2002, 33:109-111.
50. Cagliani R., Comi G.P., Tancredi L., et al. Primary beta-sarcoglycanopathy manifesting as recurrent exercise-induced myoglobinuria. Neuromuscul Disord 2001, 11:389-394.
51. Pena L., Kim K., Charrow J. Episodic myoglobinuria in a primary gamma-sarcoglycanopathy. Neuromuscul Disord 2010, 20:337-339.
52. Baumeister S., Todorovic S., Milić-Rasić V., et al. Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopathy. Neuromuscul Disord 2009, 19:167-171.
53. Politano L., Nigro V., Passamano L., et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001, 11:178-185.
54. Fanin M., Melacini P., Boito C., et al. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord 2003, 13:303-309.
55. Klinge L., Dekomien G., Aboumousa A., et al. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?. Neuromuscul Disord 2008, 18:934-941.
56. Vorgerd M., Glencik M., Mortier J., et al. Isolated loss of γ-sarcoglycan: diagnostic implications in autosomal recessive limb-girdle muscular dystrophy. Muscle Nerve 2001, 24:421-424.
57. Vainzof M., Moreira E.S., Canovas M., et al. Partial α-sarcoglycan deficiency with retention of the dystrophin-glycoprotein complex in a LGMD2D family. Muscle Nerve 2000, 23:984-988.
58. Trabelsi M., Kavian N., Fatma D., et al. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet 2008, 16:793-803.
59. Mendell J., Rodino-Klapac L., Rosales-Quintero X., et al. Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins. Ann Neurol 2009, 66:290-297.
60. Brockington M., Blake D.J., Prandini P., et al. Mutations in the Fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of α-dystroglycan. Am J Hum Genet 2001, 69:1198-1209.
61. Brockington M., Yuva Y., Prandini P., et al. Mutations in the Fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001, 10:2851-2859.
62. Mathews K.D., Stephan C.M., Laubenthal K., et al. Myoglobinuria and muscle pain are common in patients with limb-girdle muscular dystrophy 2I. Neurology 2011, 76:194-195.
63. Lindberg C., Sixt C., Oldfors A. Episodes of exercise-induced dark urine and myalgia in LGMD 2I. Acta Neurol Scand 2012, 125:285-287.
64. Hanisch F., Grimm D., Zierz S., et al. Frequency of the FKRP mutation c.826C>A in isolated hyperCKemia and in limb girdle muscular dystrophy type 2 in German patients. JNeurol 2010, 257:300-301.
65. Sveen M.L., Schwartz M., Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol 2006, 59:808-815.
66. Stensland E., Lindal S., Jonsrud C., et al. Prevalence, mutation spectrum and phenotypic variability in Norwegian patients with limb girdle muscular dystrophy 2I. Neuromuscul Disord 2011, 21:41-46.
67. Fanin M., Nascimbeni A., Aurino S., et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009, 72:1432-1435.
68. Kang P., Feener C., Estrella E., et al. LGMD2I in a North American population. BMC Musculoskelet Disord 2007, 8:115.
69. Poppe M., Cree L., Bourke J., et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003, 60:1246-1251.
70. Wahbi K., Meune C., Hamouda E.H., et al. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. Neuromuscul Disord 2008, 18:650-655.
71. Bourteel H., Vermersch P., Cuisset J.M., et al. Clinical and mutational spectrum of limb-girdle muscular dystrophy type 2I in 11 French patients. JNeurol Neurosurg Psychiatry 2009, 80:1405-1408.
72. Palmieri A., Manara R., Bello L., et al. Cognitive and MRI findings in limb-girdle muscular dystrophy 2I. JNeurol 2011, 258:1312-1320.
73. Fischer D., Walter M.C., Kesper K., et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. JNeurol 2005, 252:538-547.
74. Hicks D., Sarkozy A., Muelas N., et al. Afounder mutation in anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011, 134:171-182.
75. Tsutsumi S., Kamata N., Vokes T., et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphaseal dysplasia (GDD). Am J Hum Genet 2004, 74:1255-1261.
76. Bolduc V., Marlow G., Boycott K., et al. Recessive mutations in the putative calcium-activated chloride channel anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010, 86:213-221.
77. Jarry J., Rioux M., Bolduc V., et al. Anovel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. Brain 2007, 130:368-380.
78. Penttilä S., Palmio J., Suominen T., et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012, 78:897-903.
79. Milone M., Liewluck T., Winder T., et al. Amyloidosis and exercise intolerance in ANO5 muscular dystrophy. Neuromuscul Disord 2012, 22:13-15.
80. Sarkozy A., Deschauer M., Carlier R.Y., et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscul Disord 2012, 22:S122-S129.
81. Cao H., Hegele R.A. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000, 9:109-112.
82. De Sandre-Giovannoli A., Chaouch M., Kozlov S., et al. Homozygous defects in LMNA, encoding lamin A/C nuclear envelop proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002, 70:726-736.
83. Goizet C., Ben Yaou R., Demay L., et al. Anew mutation of the lamin A/C gene leading to autosomal dominant axonal neuropathy, muscular dystrophy, cardiac disease, and leukonychia. JMed Genet 2004, 41:e29.
84. Novelli G., Muchir A., Sangiuolo F., et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002, 71:426-431.
85. Csoka A.B., Cao H., Sammak P.J., et al. Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes. JMed Genet 2004, 41:304-308.
86. Fatkin D., MacRae C., Sasaki T., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. NEngl J Med 1999, 341:1715-1724.
87. Renou L., Stora S., Ben Yaou R., et al. Heart-hand syndrome of Slovenian type: a new kind of laminopathy. JMed Genet 2008, 45:666-671.
88. Navarro C.L., De Sandre-Giovannoli A., Bernard R., et al. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 2004, 13:2493-2503.
89. Decaudain A., Vantyghem M.C., Guerci B., et al. New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. JClin Endocrinol Metab 2007, 92:4835-4844.
90. Muchir A., Bonne G., van der Kooi A.J., et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 2000, 9:1453-1459.
91. Bonne G., Di Barletta M.R., Varnous S., et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999, 21:285-288.
92. Di Barletta M.R., Ricci E., Galluzi G., et al. Different mutations in the LMNA gene cause autosomal dominant and recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000, 66:1407-1412.
93. Quijano-Roy S., Mbieleu B., Bönnemann C., et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008, 64:177-186.
94. Rankin J., Auer-Grumbach M., Bagg W., et al. Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C. Am J Med Genet A 2008, 146A:1530-1542.
95. Benedetti S., Menditto I., Degano M., et al. Phenotypic clustering of lamin A/C mutations in neuromuscular patients. Neurology 2007, 69:1285-1292.
96. Bonne G., Mercuri E., Muchir A., et al. Clinical and molecular spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000, 48:170-180.
97. Sewry C.A., Brown S.C., Mercuri E., et al. Skeletal muscle pathology in autosomal dominant Emery-Dreifuss muscular dystrophy with lamin A/C mutations. Neuropathol Appl Neurobiol 2001, 27:281-290.
98. Park Y.E., Hayashi Y.K., Goto K., et al. Nuclear changes in skeletal muscle extend to satellite cells in autosomal dominant Emery-Dreifuss muscular dystrophy/limb-girdle muscular dystrophy 1B. Neuromuscul Disord 2009, 19:29-36.
99. Available at: . http://www.jain-foundation.org/lgmd-subtyping-tool/.